- Home
- KZIA vs AIMD Comparison
KZIA vs AIMD Comparison
Compare KZIA & AIMD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | KZIA | AIMD |
|---|---|---|
| Founded | 1994 | 1984 |
| Country | Australia | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 161.5M | 10.2M |
| IPO Year | 1999 | N/A |
Fundamental Metrics
Financial Performance| Metric | KZIA | AIMD |
|---|---|---|
| Price | $6.40 | $2.00 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 3 | 0 |
| Target Price | ★ $17.67 | N/A |
| AVG Volume (30 Days) | ★ 241.3K | 24.7K |
| Earning Date | 12-26-2025 | 11-13-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $1,199,108.00 | $113,037.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 178.19 |
| 52 Week Low | $2.86 | $1.78 |
| 52 Week High | $17.40 | $5.00 |
Technical Indicators
Market Signals| Indicator | KZIA | AIMD |
|---|---|---|
| Relative Strength Index (RSI) | 36.33 | 36.71 |
| Support Level | $6.65 | $1.94 |
| Resistance Level | $11.06 | $2.18 |
| Average True Range (ATR) | 1.97 | 0.11 |
| MACD | -0.71 | 0.01 |
| Stochastic Oscillator | 0.00 | 15.00 |
Price Performance
Historical ComparisonAbout KZIA Kazia Therapeutics Limited
Kazia Therapeutics Ltd is a biotechnology company focused on pharmaceutical drug development in oncology. The company has a portfolio of development candidates across various technologies targeting multiple cancer indications. Its primary program is Paxalisib, an investigational brain-penetrant inhibitor of the PI3K/Akt/mTOR pathway, designed for the treatment of brain cancer. The company develops targeted therapies aimed at addressing medical needs in oncology. The company operates in Australia and the United States.
About AIMD Ainos Inc.
Ainos Inc is a dual-platform AI and biotech company pioneering smelltech and immune therapeutics. Its AI Nose platform and smell language model (SLM) digitize scent into Smell ID, a machine-readable data format, powering intelligent sensing across robotics, smart factories, and healthcare. The company also develops VELDONA, a low-dose oral interferon targeting rare, autoimmune, and infectious diseases. It combines AI and Nose, redefining machine perception for the sensory age.